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Background: Congenital factor XIII (FXIII) deficiency is an extremely rare 
bleeding disorder (RBD) with different clinical coagulation disorders and great 
impacts on the perioperative patient outcome. Its prevalence in Southeast Iran 
is approximately 4,000 times higher than the worldwide prevalence, with 
Trp187Arg (c.559T> C) as the only causative mutation of FXIII deficiency 
(FXIIID) there. We investigated the founder effect of rs1742924, rs4960181, 
rs3778360 and rs4142290 using haplotype analysis to define the genetic 
phenomenon in this geographic region. 
Materials and Methods: In a case-control study, 10 patients with FXIIID and 
10 healthy individuals were assessed. Initially, Trp187Arg (c.559T>C) 
mutation was assessed in all study populations using a PCR-RFLP technique, 
then haplotype analysis was performed by assessing rs1742924, rs4960181, 
rs3778360, and rs4142290 polymorphisms. Data were analyzed using a two-
proportion z-test. 
Results: All patients were homozygote for Trp187Arg (c.559T>C), and this 
mutation was not observed in any form of homozygote or heterozygote in the 
control group. Polymorphisms in rs1742924, rs4960181, and rs377836 were 
homozygote (TT, GG, GG, respectively) and T, G, and G alleles distribution in 
cases and controls with significant difference (P<0.001, P<0.001, and P=0.01 
respectively). Rs4142290 polymorphism showed no significant difference 
between patients and controls (P=0.3). Two types of haplotypes were observed 
in the case group, and haplotype number 1* was observed among 90% of them, 
while not observed in the control group.  
Conclusion: It seems that founder effectors of haplotype number *1 have more 
antiquity versus other haplotypes, and probably founder effect is responsible 
for this high prevalence of FXIIID in the southeast of Iran. 
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Introduction 
Coagulation Factor 13 (FXIII) is a member of the 
transamidases family that is present in the blood 
circulation system in the form of heterotetramer 
(FXIII-A2B2), including two catalytic A subunits 
(FXIII-A2) and two non-catalytic (carriers) B subunits 
(FXIII-B2) (1). FXIII at the end of the coagulation 
cascade will create a strong and stable fibrin clot by 
creating cross-linking and isopeptide bonds between 
the amino acids lysine and glutamine of fibrin 
monomers (2).  
Congenital Deficiency of Coagulation FXIII 
(FXIIID) is one of the extremely rare bleeding 
disorders with a prevalence of 1 in 2 million people in 
the general population and with autosomal recessive 
inheritance (3). Deficiency of this coagulation factor is 
due to mutations in the A subunit or B subunit gene, 
but the mutations of A subunit are much more than B 
subunit, so far more than 155 mutations have been 
observed in A subunit gene (4, 5). FXIIID causes a lack 
of consistency and persistence of fibrin clots at the end 
of the coagulation process, and subsequently, the fibrin 
clots formed by the body's fibrinolytic system 
decompose, and in this spontaneous miscarriage and 
delayed wound healing occur in the patient (2). 
Unfortunately, it is not possible to diagnose 
this coagulation disorder with routine coagulation 
tests, Bleeding Time, Prothrombin Time, Partial 
Thromboplastin Time, and platelet count tests are 
normal in these patients (6). Typically, clot solubility 
in 5-molar urea or monochloroacetic acid (1%) is used 
to diagnose the disease. Of course, this method does 
not identify all types of coagulation FXIII deficiency, 
so more accurate tests such as quantitative and 
antigenic measuring of factors and molecular studies 
are used to confirm patients (7).  
For the treatment of patients with coagulation 
FXIIID, preventive treatments such as fresh frozen 
plasma (FFP) and cryo-precipitation are usually 
recommended. Today, however, drugs such as 
Fibrogammin P as well as recombinant FXIII have 
been used, which are helpful (8, 9). 
Although the congenital deficiency of factor 
13 in coagulation has a very low prevalence in the 
world (1 in 2 million people), but the prevalence of this 
hemorrhagic disorder in Iran is very high, since more 
than 500 patients with the disorder have been 
identified. Sistan and Baluchestan province, with a 
population of 2.775 million and a high rate of 
consanguineous marriages, with 410 patients and 
approximately 4,000 times higher than the worldwide 
prevalence, has the highest frequency of coagulation 
FXIIID, not only in Iran but throughout the world (10, 
11). Several molecular studies have been performed on 
a significant number of patients, all of them suggest 
that a common homozygous mutation (Trp187Arg 
(c.559T> C)) causes TGG to CGG deformity in Exon 
4 of A subunit gene on chromosome 6 is present in all 
patients, which change Arginine to Tryptophan (8, 10, 
12-15).  
The presence of such a same mutation in all 
patients with coagulation FXIIID in Sistan and 
Baluchestan province may indicate a common ancestry 
or a founder effect in this population (12-14). In 
general, the founder effect occurs when a small group 
of immigrants creates a new genetic population in an 
area. Populations affected by the founder effect often 
have small populations with intra-racial marriages and 
therefore are sensitive to genetic drift, which in turn 
reduces genetic diversity in these populations, and 
subsequently, due to a significant decrease of genetic 
diversity, the newly formed population may be 
genetically and phenotypically distinct from the 
original population (16-20). The present study used 
molecular analysis of rs1742924, rs4960181, 
rs3778360, rs4142290) to molecularly investigate the 
founder effect to examine the possible role of the 
founder effect in increasing the prevalence of this 
disease in southeast Iran. 
Methods 
Case and control population (Samples): The present 
case-control study was performed on 10 patients with 
congenital FXIIID and 10 healthy individuals. 
Initially, a questionnaire on demographic 
characteristics including age, sex, city of residence, age 
of diagnosis, first clinical sign, family history of 
FXIIID, and type of treatment for each patient was 
completed by experienced laboratory staff. 
DNA extraction: To isolate the DNA, 2 ml of blood 
samples were collected from healthy controls and 
patients in a tube containing anticoagulant EDTA, then 
genomic DNA was extracted from the white blood 
cells of the samples by Kit (Yekta Tajhiz Azma, Iran), 
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and to determine the quality of the extracted DNA, the 
concentration of the samples was determined by 
Biophotometer (Eppendorf), and also all samples were 
electrophoresed on 1% agarose gel to ensure the 
presence of DNA samples. 
Molecular studies: FXIII mutation; Trp187Arg; 
(c.559T> C): Initially, all patients and the control 
group were examined for Trp187Arg mutation 
(c.559T> C). To perform this, genomic DNA was 
replicated using PCR (Polymerase chain reaction), and 
then 861 basepairs product of PCRs were treated by the 
restrictive enzyme Eco130I (Fermentas Life Sciences, 
York, UK). This enzyme produces three fragments of 
601, 192, and 68 base pairs (bp) in those without 
mutations, while homozygotes produce only two 
fragments of 669 and 192 bp, and heterozygotes 
produce fragments with the size of 601, 669, 192, and 
68 bp (Table 1). 
Polymorphisms of rs1742924, rs4960181, 
rs3778360, and rs4142290: To investigate the 
haplotype polymorphisms, rs1742924, rs4960181, 
rs3778360, rs4142290 were selected within the FXIII 
gene (chromosome 6). All selected polymorphisms are 
approved by Hapmap and have a Global MAF of about 
0.5 to be Informative. Initially, all studied patients and 
the control group were evaluated for these 
polymorphisms. To do this, genomic DNA was 
amplified using PCR, then the products were 
sequenced, and finally, the sequences were viewed by 
CLCSequenceViewer-6-8-1 and Chromas261 software 
(Table 2). 
Statistical analysis: all data were analyzed by Minitab 
software using a two-proportion z-test, and the results 
were considered statistically meaningful with a P value 
less than 0.05. 
Results 
Characteristics of the studied individuals  
Among 10 patients with coagulation FXIIID, 4 were 
male (40%) and 6 were female (60%). The mean age 
and mean age of diagnosis were 15 and 1.9 years, 
respectively. The average age of male patients was 
7.75 years and in women, it was 19.83 years. The mean 
age of diagnosis in male patients was 1.54 years and in 
female patients was 2.10 years. Among the 10 control 
group members, 3 were males (30%) and 7 were 
females (70%), and the mean age of healthy males was 
23.33 years and 17.57 years in females. 
FXIII mutation (Trp187Arg; c.559T> C) 
Trp187Arg mutation (c.559T> C) was observed in 
people with suspected coagulation FXIIID as 669 and 
192 bp fragments, which indicate the same form of 
homozygous (C / C) of the disease. In the control 
group, fragments with the size of 601, 192, and 68 bp 
were observed, which indicates the absence of 
mutation and consequently no FXIIID (Figure 1). 
Polymorphism rs1742924 (NC_000006.12: 
g.6242713T> C): After obtaining the single-band 
 
Figure 1. PCR enzyme digestion result for Trp187Arg mutation (c.559T> C) 
L: Ladder (100bp)                                                                                                                                                
A1-12: Homozygous (669bp-192bp) 
B1-2:   Hetrozygote (669bp-192bp-68bp-601bp) 
C: PCR product (861bp) 
D: Non mutant sample (601bp-192bp-68bp). 
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fragments, the products of PCR were sequenced. The 
results of sequencing were checked in Chromas 
software. The results analysis of patient and control 
group sequence in Chromas software, CLC sequence 
viewer, and Minitab and using two-proportion z-test 
for polymorphism rs1742924 showed that this 
polymorphism occurs in all patients as T / T 
homozygote; however, it was different in the control 
 
Figure 2. Results of PCR reaction sequence and genotyping for polymorphism rs1742924 (Negative Strand). 
 
Figure 3. Results of  PCR reaction product sequence determination and genotyping for polymorphism rs4960181 
(Negative Strand). 
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group (C / C and T / C), and statistical studies showed 
that the distribution of allele T was significantly 
different between the two groups of patients and 
control (P <0.001) (Figure 2). 
Polymorphism rs4960181 (NC_000006.12: 
g.6269065G> C): After obtaining the single-band 
fragments, the products of PCR were sequenced. The 
results of sequencing were checked in Chromas 
software. The results analysis of patient and control 
group sequence in Chromas software, CLC sequence 
viewer, and Minitab and using two-proportion z-test 
for polymorphism rs4960181 showed that this 
polymorphism occurs in all patients as G / G 
homozygous but differs in the control group (G / G and 
C / C), Statistical studies also showed that the 
distribution of allele G was significantly different in 
the two groups of patients and control (P <0.001) 
(Figure 3). 
Polymorphism rs3778360 (NC_000006.12: 
g.6150132G> A): After obtaining the single-band 
fragments, the products of PCR were sequenced. The 
results of sequencing were checked in Chromas 
software. The results analysis of patient and control 
group sequence in Chromas software, CLC sequence 
viewer, and Minitab and using two-proportion z-test 
for polymorphism rs3778360 showed that this 
polymorphism occurs in all patients as G / G 
homozygous; however, it was different in the control 
group (G / G, A / A, and G / A), and statistical studies 
also showed that the distribution of allele G was 
significantly different in the two groups of patients and 
control (P = 0.01) (Figure 4). 
Polymorphism rs4142290 (NC_000006.12: 
g.6154374G> C): After obtaining the single-band 
fragments, the products of PCR were sequenced. The 
results of sequencing were checked in Chromas 
software. The results analysis of patient and control 
group sequence in Chromas software, CLC sequence 
viewer, and Minitab and using two-proportion z-test 
for polymorphism rs3778360 showed that this 
polymorphism occurs in patients as G/G and C/C 
 
Figure 4. Results of  PCR product sequencing and genotyping evaluation for polymorphism rs3778360 (Negative Strand). 
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homozygous; however, it is different in the control 
group (G / G and C / C), and statistical studies also 
showed that there is no significant difference in the 
distribution of allele G between the two groups of 
patients and control (P <0.3) (Figure 5). 
Haplotype analysis: Interpretation and haplotype 
analysis results showed that there are 2 different types 
of haplotypes in patients (No. 1 *, 2 *) that haplotype  
Table 1: Primers used in PCR reaction for Trp187Arg mutation (c.559T> C). 
Restriction enzyme PCR product (bp) Primers Mutation 
Eco130I 861 Forward: 5′ GTAACTTATGTCCGCACCTCC 3′ 




Figure 5. Results of PCR product sequencing and genotyping for polymorphism rs4142290 (positive Strand). 
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No. 2* was seen in 10% of the study population; 
however, there was a significant point about haplotype 
No. 1 * that this haplotype was observed in 90% of 
patients, in other words, 90% of the patients had the 
same haplotype block. In the control group, different 
types of haplotypes were observed compared to 






Congenital Coagulation FXIII deficiency is known as 
an extremely rare bleeding disorder with a prevalence 
of approximately 1 in 2 million people worldwide; 
despite the very low prevalence of this disease in the 
world, the prevalence rate of the disease has increased 
significantly due to consanguineous marriages in some 
geographical regions. Statistical studies and researches 
conducted in this field have shown that Sistan and 
Baluchestan province in Iran, with a prevalence more 
than of 130 patients per 1 million people; has the 
highest prevalence of congenital FXIIID in the world 
(13, 21). 
Trp187Arg mutation (c.559T> C) has been 
observed in all patients in the present study as the main 
Table 3: Results of genotypes analysis of polymorphisms rs1742924, rs4960181, rs3778360, rs4142290. 
No rs1742924 rs4960181 rs3778360 rs4142290 
 Patient Control Patient Control Patient Control Patient Control 
1 T/T C/C G/G C/C G/G G/G G/G G/G 
2 T/T C/C G/G C/C G/G G/A G/G G/G 
3 T/T C/C G/G G/G G/G A/A G/G G/G 
4 T/T C/C G/G G/G G/G G/G G/G G/G 
5 T/T C/C G/G G/G G/G A/A G/G G/G 
6 T/T C/C G/G C/C G/G G/G G/G C/C 
7 T/T T/C G/G G/G G/G G/A G/G G/G 
8 T/T T/C G/G C/C G/G G/G G/G G/G 
9 T/T T/C G/G G/G G/G A/A C/C G/G 
10 T/T C/C G/G G/G G/G G/G G/G C/C 
 P <0.001 P <0.001 P = 0.01 P <0.3 
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cause of coagulation factor XIII deficiency in Sistan 
and Baluchestan province (12). In 2010, Tamaddon et 
al, conducted a study on 23 people (including 10 
patients and 13 members of patients' families) from 
non-consanguineous families. They used molecular 
methods such as sequencing, PCR-RFLP, and CFGE 
to evaluate all exons of coagulation FXIII in these 
patients, and they concluded that the mutation in 
c.559T> C was homozygous (CC) in all patients 
studied (22). 
Trinh et al suggested that the presence of a 
similar mutation in different non-related families with 
FXIIID in southeastern Iran (Sistan and Baluchestan 
Province) may indicate a common ancestry or founder 
effect in this population (14). The founder effect is one 
of how nature creates new species from the original 
population. In fact, in population genetics, the 
reduction in genetic diversity caused by the creation of 
a new population by a small number of people 
belonging to a large population is called the founder 
effect. The newly formed population may be 
genetically and phenotypically distinct from the 
original population (23-25). 
Important examples in this regard include the 
Ashkenazi Jewish population, which has the highest 
prevalence of congenital factor XI deficiency in the 
world, in one study, haplotype analysis was performed 
to examine a group of patients with factor XI 
deficiency which confirmed the founder effect in the 
mutation of type II of factor XI and concluded that the 
mutation of type ІІ factor XI occurred more than 120 
generations ago (26, 27). 
In the present study, a significant point was 
related to polymorphisms rs1742924, rs4960181, and 
rs377836; which were homozygous in patients (TT, 
GG, and GG, respectively); besides, in each 
polymorphism, the distribution of alleles (T, G, and G, 
respectively) had a significant difference between the 
two groups of patients and control (P <0.001, P <0.001, 
and P = 0.01, respectively), however, polymorphism 
rs4142290 was present in 9 patients in the form of GG 
homozygote and one patient as CC homozygote; also, 
no significant difference was observed between the 
distribution of allele G between the two groups of 
patients and control (P = 0.3). 
Following the interpretation and analysis, the 
haplotype results showed that there are 2 different 
types of haplotypes in patients (1 *, 2 *) that haplotype 
number 2 * was seen in 10% of the study population, 
but there was a significant point about haplotype No. 1 
* that this haplotype was present in 90% of patients, in 
other words, 90% of the patients had the same 
haplotype block. In the control group, different 
haplotypes were observed compared to patients. 
The rs1742924, rs4960181, and rs377836 
polymorphisms were significantly different in the 
patient and control group; besides, it was noted that 
haplotype No. 1 * of the patients’ group was observed 
in 90% of this group, it could indicate the genetic 
association of the polymorphisms with the mutation 
Trp187Arg (c.559T>C), and subsequently, this genetic 
association could indicate a kind of founder effect in 
this disease. In other words, there have been people 
with pathogenic genes in previous generations who 
have increased the prevalence of the pathogenic gene 
in the population of southeast Iran as a result of 
interracial marriages and lower genetic diversity. 
According to the above, one of the most 
important and influential factors in increasing the 
prevalence of the disease is congenital coagulation 
FXIIID in Sistan and Baluchestan province is 
consanguineous marriages. Interestingly, all patients in 
this study have parents with a first-degree family 
relationship (cousins). Previous studies have also 
Table 4: Results of Haplotype analysis of patients with coagulation FXIIID. 
Frequency rs1742924 rs4960181 rs3778360 rs4142290 Haplotype 
9/10 (90%) T G G G 1* 
1/10 (10%) T G G C 2* 
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shown that more than 70% of patients with FXIIID in 
southeast Iran have parents with a close relationship 
(cousins); while only 10% of patients' parents have no 
relationship (12, 21). 
The highest number of patients in this 
province lives in Khash and less in Zahedan and 
Saravan (45.9%, 18.5%, and 13.7%, respectively). 
Interestingly, according to studies, the source of the 
disease in the city of Khash, and almost all patients or 
their ancestors have migrated from this city to other 
cities in the province (11, 28-29). This resemblance in 
the race is an important and helpful factor in increasing 
consanguineous marriages and consequently 




The present study showed that there is a genetic 
linkage between polymorphisms rs1742924, 
rs4960181, and rs377836 with a mutation in 
Trp187Arg (c.559T> C). It seems that founder 
effectors of haplotype number *1 have more antiquity 
versus other haplotypes, and probably founder effect is 
responsible for this high prevalence of FXIIID in the 
southeast of Iran. 
 
Acknowledgment 
This study was supported by Grant No. 94-05-31-
27408 from Iran University of Medical Sciences. 
 
Conflicts of Interest  
The authors declare that they have no conflict of 





1. Lorand L. Factor XIII: structure, activation, and interactions with 
fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291-311. 
2. Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor 
XIII: a coagulation factor with multiple plasmatic and cellular 
functions. Physiol Rev. 2011;91(3):931-72. 
3. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII 
Deficiency. Semin Thromb Hemost. 2009;35(4):426-38. 
4. Anwar R, Gallivan L, Miloszewski KJ, Markham AF. Factor XIII 
deficiency causing mutation, Ser295Arg, in exon 7 of the factor XIIIA 
gene. Thromb Haemost. 2000;84(4):591-4. 
5. Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and 
factor XIII deficiency. Blood Rev. 2016;30(6):461-75. 
6. Jennings I, Kitchen S, Woods TA, Preston FE. Problems relating 
to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS 
study. J Thromb Haemost. 2003;1(12):2603-8. 
7. Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. Diagnosis 
and classification of factor XIII deficiencies. J Thromb Haemost. 
2011;9(7):1404-6. 
8. Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, 
Shamsizadeh M, et al. Clinical manifestations and management of 
life-threatening bleeding in the largest group of patients with severe 
factor XIII deficiency. Int J Hematol. 2014;100(5):443-9. 
9. Dorgalaleh A, Kazemi A, Zaker F, Shamsizadeh M, Rashidpanah 
J, Mollaei M. Laboratory Diagnosis of Factor XIII Deficiency, 
Routine Coagulation Tests with Quantitative and Qualitative 
Methods. Clin Lab. 2016;62(4):491-8. 
10. Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Bamedi T, 
Karimi M. Molecular Analysis Of The Largest Group Of Patients 
With Factor XIII Deficiency In Southeast Of Iran. Blood. 
2013;122(21):4780. 
11. Dorgalaleh A, Tabibian S, Shams M, Majid G, Naderi M, Casini 
A, et al. A Unique Factor XIII Mutation in Southeastern Iran with an 
Unexpectedly High Prevalence: Khash Factor XIII. Semin Thromb 
Hemost. 2019;45(1):43-9. 
12. Dorgalaleh A, Assadollahi V, Tabibian S, Shamsizadeh M. 
Molecular Basis of Congenital Factor XIII Deficiency in Iran. Clin 
Appl Thromb Hemost. 2018;24(2):210-6. 
13. Trinh CH, Sh Elsayed W, Eshghi P, Miri-Moghaddam E, Zadeh-
Vakili A, Markham AF, et al. Molecular analysis of sixteen unrelated 
factor XIIIA deficient families from south-east of Iran. Br J Haematol. 
2008;140(5):581-4. 
14. Eshghi P, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, 
et al. Arg77His and Trp187Arg are the most common mutations 
causing FXIII deficiency in Iran. Clin Appl Thromb Hemost. 
2012;18(1):100-3. 
15. Cromie GA, Leach DR. Control of crossing over. Mol Cell. 
2000;6(4):815-26. 
16. Ott J, Wang J, Leal SM. Genetic linkage analysis in the age of 
whole-genome sequencing. Nat Rev Genet. 2015;16(5):275-84. 
17. Sprecher CJ, Puers C, Lins AM, Schumm JW. General approach 
to analysis of polymorphic short tandem repeat loci. Biotechniques. 
1996;20(2):266-76. 
18. Ferreira MA. Linkage analysis: principles and methods for the 
analysis of human quantitative traits. Twin Res. 2004;7(5):513-30. 
19. Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and 
mortality in a large number of Iranian patients with severe congenital 
Probability of Occurrence Founder Effect in FXIII Deficiency Patients …                                                   Shahraki et al. 
Vol 5, No 3, Summer 2020 
233 
factor XIII deficiency. Ann Hematol. 2016;95(3):451-5. 
20. Tamaddon G, Kazemi A, Rastgarlari G, Ala F, Hejazi S. 
Molecular Basis of Inherited Factor XIII- A Deficiency among 
Patients from Sistan - Baluchestan . Zahedan J Res Med Sci 
2010;11(4):e94357. 
21. Pulst SM. Genetic linkage analysis. Arch Neurol. 
1999;56(6):667-72. 
22. Rahim NG, Harismendy O, Topol EJ, Frazer KA. Genetic 
determinants of phenotypic diversity in humans. Genome Biol. 
2008;9(4):215. 
23. Papachristou C, Lin S. Microsatellites versus Single-Nucleotide 
Polymorphisms in confidence interval estimation of disease loci. 
Genet Epidemiol. 2006;30(1):3-17. 
24. Duga S, Salomon O. Congenital factor XI deficiency: an update. 
Semin Thromb Hemost. 2013;39(6):621-31. 
25. Wheeler AP, Gailani D. Why factor XI deficiency is a clinical 
concern. Expert review of hematology. 2016;9(7):629-37. 
26. Naderi M, Alizadeh S, Tabibian S, Hosseini S, Varmaghani B, 
Shamsizadeh M, et al. Effect of Social Factors on the Highest Global 
Incidence of Congenital Factor XIII Deficiency in Southeast of Iran. 
Arch Iran Med. 2015;18(5):331. 
27. Wheeler AP, Gailani D. Why factor XI deficiency is a clinical 
concern. Expert Rev Hematol. 2016;9(7):629-37. 
28. Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi 
T, et al. Diagnosis, clinical manifestations and management of rare 
bleeding disorders in Iran. Hematology. 2017;22(4):224-30. 
29. Mirakhorli M, Behboudi Farahbakhsh F, Reza Baghaipour M, 
Mahmoudi T, Jazebi M, Tabatabaei SM, et al. Factor XIII mutation 
spectrum in Iranian patients with hereditary factor XIII deficiency: 
Detection of 3 novel mutations. Int J Lab Hematol. 2019;41(3):e61-
e5. 
30. Payandeh M, Rahimi Z, Kansestani AN, Hemmati S, Aleyasin M, 
Zare ME, et al. Clinical features and types of von Willebrand disease 
in women with menorrhagia referred to hematology clinic of 
kermanshah. Int J Hematol Oncol Stem Cell Res. 2013;7(2):1-5. 
31. Tavasoli B, Safa M, Dorgalaleh A, Ghasemi JB, Rezaei Makhouri 
F, Rezvani MR, et al. Molecular and clinical profile of congenital 
fibrinogen disorders in Iran, identification of two novel mutations. Int 
J Lab Hematol. 2020. 
 
 
